MXPA05013958A - Tratamiento de cancer con epotilona. - Google Patents

Tratamiento de cancer con epotilona.

Info

Publication number
MXPA05013958A
MXPA05013958A MXPA05013958A MXPA05013958A MXPA05013958A MX PA05013958 A MXPA05013958 A MX PA05013958A MX PA05013958 A MXPA05013958 A MX PA05013958A MX PA05013958 A MXPA05013958 A MX PA05013958A MX PA05013958 A MXPA05013958 A MX PA05013958A
Authority
MX
Mexico
Prior art keywords
epothilones
cancer treatment
administration
treatment
epotilone
Prior art date
Application number
MXPA05013958A
Other languages
English (en)
Inventor
Sara Zaknoen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05013958A publication Critical patent/MXPA05013958A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

El uso de una epotilona para el tratamiento de una enfermedad proliferativa, el cual comprende el paso de administrar diariamente una cantidad terapeuticamente efectiva de una epotilona mediante administracion intravenosa (i.v.) continua.
MXPA05013958A 2003-06-27 2004-06-25 Tratamiento de cancer con epotilona. MXPA05013958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48326303P 2003-06-27 2003-06-27
PCT/EP2004/006921 WO2005000292A1 (en) 2003-06-27 2004-06-25 Cancer treatment with epothilones

Publications (1)

Publication Number Publication Date
MXPA05013958A true MXPA05013958A (es) 2006-02-24

Family

ID=33552048

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013958A MXPA05013958A (es) 2003-06-27 2004-06-25 Tratamiento de cancer con epotilona.

Country Status (9)

Country Link
US (1) US20060205795A1 (es)
EP (1) EP1641449A1 (es)
JP (1) JP2009513486A (es)
CN (1) CN1812780A (es)
AU (1) AU2004251444B2 (es)
BR (1) BRPI0412000A (es)
CA (1) CA2530311A1 (es)
MX (1) MXPA05013958A (es)
WO (1) WO2005000292A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002393A (es) * 2003-09-02 2006-06-20 Novartis Ag Tratamiento de cancer con epotilomas.
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
JP2006504743A (ja) * 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤

Also Published As

Publication number Publication date
CA2530311A1 (en) 2005-01-06
JP2009513486A (ja) 2009-04-02
US20060205795A1 (en) 2006-09-14
EP1641449A1 (en) 2006-04-05
AU2004251444A1 (en) 2005-01-06
WO2005000292A1 (en) 2005-01-06
BRPI0412000A (pt) 2006-08-15
AU2004251444B2 (en) 2008-05-22
CN1812780A (zh) 2006-08-02

Similar Documents

Publication Publication Date Title
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
AU2003245338A1 (en) Plunger assembly for patient infusion device
AU2003244890A1 (en) An infusion device for medical use.
HK1116339A1 (en) Methods of administering epothilone analogs for the treatment of cancer
WO2007010273A3 (en) Use of thiazole derivatives and analogues in the treatment of cancer
HK1111084A1 (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
WO2004006859A3 (en) Platinum compound
UA83798C2 (ru) Применение эпотилонов в лечении заболеваний мозга, ассоциированных с пролиферативными процессами
AU2003243561A1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MY146794A (en) Use of an alpha-2-delta ligand for the treatment of luts
AU2003294796A1 (en) Epothilone analogs for site specific delivery in the treatment of proliferative diseases
HRP20121052T8 (en) A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy
HK1086493A1 (en) Treatment of proliferative diseases with epothilone derivatives and radiation
MXPA05013958A (es) Tratamiento de cancer con epotilona.
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
ZA200405342B (en) The use of melagatran for the manufacture of a medicament for the treatment of type i diabetes mellitus
AU2003296545A1 (en) Use of a trpm8-activating substance for the treatment of tumours
WO2005079769A3 (en) Piperazine derivatives for the treatment of endometriosis
AU2002359635A1 (en) Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
AU2002335304A1 (en) The use of berberine as insulin sensitizer
DE602004022578D1 (de) Antitumorale terpen-verbindungen
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
RS52038B (en) USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS
BRPI0415428A (pt) formulações terapêuticas
AU2003216959A1 (en) Derivatives of thiazoles used for the treatment of neurological diseases

Legal Events

Date Code Title Description
FA Abandonment or withdrawal